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Abstract
Background: Hepatitis is a serious blood born infection in patients withβ-thalassemia major (β-TM). There was no previous report
on hepatitis prevalence in patients with β-TM in Zabol, Iran.
Objectives: The current study aimed to evaluate characteristics of hepatitis in patients withβ-TM visiting Imam Khomeini Hospital
of Zabol, in Sistan and Baluchistan province of Iran.
PatientsandMethods: There were 90 patients withβ-TM. General demographic and laboratory results were obtained by interviews
and reviewing clinical and laboratory histories. Data for anti-HCV, HBs antigen and anti-HBs were extracted from latest archived
records, and analyzed using SPSS ver. 19.
Results: Males and females comprised 51% and 49% of the patients, respectively. Mean age of the patients was 14.8±7.4 years old.
Anti-HCV and HBs antigen were detected in 10% and 3.3% of the patients, respectively. Significant difference was found between the
mean age of anti-HCV positive (20.1± 3.6, 95% CI: 17.3 - 22.9) and negative (14.2± 7.5, 95% CI: 12.5 - 15.9) patients (P = 0.02). Mean
ferritin value was measured 4702± 2743 ng/mL. A significant correlation was observed between serum ferritin level and age (r =
0.3, P = 0.01). Hepatic enzymes, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) had mean levels of 51.8± 32.8
IU/L and 58.8± 59 IU/L, respectively. No significant association was identified between hepatitis status and either ferritin or hepatic
enzymes levels.
Conclusions: Results demonstrated the relatively high prevalence of HCV infection in the patients. Applying sensitive methods to
screen blood units is recommended to minimize the risk of transfusion associated hepatitis.
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1. Background
Thalassemia constitutes a major general-health prob-
lem in Iran (1, 2), and β-thalassemia major (β-TM) is the
most common cause of thalassemia major in Iranians. In
addition to psychological and financial burdens, encoun-
tering adverse effects of transfusion therapy represents a
dilemma for patients withβ-TM and their families. Accord-
ingly, transmission of hepatitis infections renders as con-
cerning sequel of repeated transfusions in patients with
β-TM (3). In fact, hepatitis is responsible for a large spec-
trum of liver dysfunctions including hepatic enzymes ab-
normalities, hepatic fibrosis and cirrhosis (4, 5).
Relatively high frequencies of both β-TM and hepati-
tis are reported in Sistan and Baluchistan province (2, 6).
Therefore, patients with β-TM are at significantly high risk
of being infected with hepatitis through transfusion of do-
nated blood units. Despite this fact, there is no report on
frequency and features of hepatitis infection in transfu-
sion dependent patients with β-TM in Zabol.
2. Objectives
The current study aimed to evaluate the seroepidemi-
ology and clinical significance of anti-HCV, HBs antigen
and anti-HBs in patients withβ-TM seeking medical care in
Imam Khomeini Hospital of Zabol.
3. Materials andMethods
This descriptive cross-sectional study was carried out
in 2014. Consent form was signed by the patients or their
parents before entering into the study. Authors inter-
viewed and checked clinical records of 90 patients with β-
TM regularly visiting Imam Khomeini hospital of Zabol to
obtain demographic and general laboratory data.
Positivity for anti-HCV, HBs antigen and anti-HBs were
determined using latest clinical records of the patients.
Subsequently, data were transferred into SPSS ver.19 soft-
ware; and then descriptive and inferential statistical anal-
yses were carried out using Chi-square test, standard inde-
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pendent sample t-test, one-way ANOVA and logistic regres-
sion for the intended variables.
4. Results
Distribution of two genders in the selected sample was
51% males and 49% females. Mean age of the patients was
14.8 ± 7.4 years old. Mean ferritin value was 4702 ± 2743
ng/mL; while mean serum values of aspartate transami-
nase (AST) and alanine transaminase (ALT) enzymes were
measured 51.8± 32.8 IU/L and 58.8± 59 IU/L, respectively.
Table 1 shows general features of the studied population in-
cluding age groups and health status of spleen and liver.
Table 1. Clinical and Laboratory Characteristics of Patients Withβ-Thalassemia Ma-
jor
Characteristics Gender Total
Male (N = 46) Female (N = 44)
Age groups, y
< 10 12 22 34 (37.8)
10 - 20 25 17 42 (46.7)
> 20 9 5 14 (15.6)
Spleen status
Normal 15 18 33 (36.6)
Splenectomy 18 12 30 (33.3)
Splenomegaly 13 14 27 (30)
Liver status
Normal 39 39 78 (86.6)
Hepatomegaly 7 5 12 (13)
AST, IU/L
Normal (5 - 40) 17 23 40 (44.4)
Abnormal low (<
5)
0 0 0
Abnormal high (>
40)
29 21 50 (55.6)
ALT, IU/L
Normal (5 - 40) 25 20 45 (50)
Abnormal low (<
5)
0 1 1 (1.1)
Abnormal high (>
40)
21 23 44 (48.9)
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase.
Anti-HCV was identified in nine out of 90 patients (10%),
and HBs antigen was positive in three (3.3%) patients. Re-
garding anti-HBs, 68 (75.6%) subjects were immune (anti-
body titer > 10 IU), 14 (15.6%) were non-immune (antibody
titer 2 - 10 IU), and 8 (8.9%) had negative results (antibody
titer < 2 IU). Significant association was observed between
anti-HCV positivity and both age and spleen condition of
the patients (respective p values of 0.01 and 0.05, Table 2).
Table2. Clinical and Laboratory Features in Anti-HCV1 Positive and Negative Patients
Withβ-Thalassemia Majora
Characteristics Anti-HCV Antibody P Value
Positive (N = 9) Negative (N = 81)
Gender 0.2
Male 3 (6.5) 43 (93.5)
Female 6 (13.6) 38 (86.4)
Age group, y 0.01
< 10 0 34 (100)
10 - 20 5 (11.9) 37 (88.1)
> 20 4 (28.6) 10 (71.4)
Spleen status 0.05
Normal 0 33 (100)
Splenectomy 5 (16.7) 25 (83.3)
Splenomegaly 4 (14.8) 23 (85.2)
Liver status 0.4
Normal 7 (9) 71 (91)
Hepatomegaly 2 (16.7) 10 (83.3)
AST (IU/L) 1
Normal (5 - 40) 4 (10) 36 (90)
Abnormal low (<
5)
0 0
Abnormal high
(> 40)
5 (10) 45 (90)
ALT, IU/L 0.5
Normal (5 - 40) 3 (6.7) 42 (93.3)
Abnormal low (<
5)
0 1 (100)
Abnormal high
(> 40)
6 (13.6) 38 (86.4)
Abbreviations: ALT, alanine transaminase; Anti-HCV1, anti-hepatitisCvirus; AST,
aspartate transaminase.
aValues are expressed as No. (%).
Mean age of anti-HCV positive patients was higher (20.1
± 3.6) than negative individuals (14.2± 7.5, P = 0.02, Table
3). Although mean serum levels of AST and ALT hepatic en-
zymes were also higher in anti-HCV positive patients, the
difference was not statistically significant. Moreover, no
association was observed between anti-HBs or HBs antigen
status and demographical or clinical parameters.
Furthermore, serum ferritin level was significantly cor-
related with age of the patients (P = 0.01). Mean value of
ferritin was significantly higher in patients > 10 years old
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Table 3. Mean Values of Age, Ferritin and Hepatic Enzymes Respective to Anti-HCV1 Positivity or Negativity and Different Age Groups
Characteristics Anti-HCV Antibody P Value Age Groups, y P Value
Positive (N = 9) Negative (N = 81) < 10 (N = 34) 10 - 20 (N = 42) > 20 (N = 14)
Age, y 0.02 0.001
Mean 20.1± 3.6 14.2± 7.5 7± 2.9 17.7± 4.2 24.9± 2.8
95% CI 17.3 - 22.9 12.5-15.9 6 - 8.1 16.4 - 19 23.3 - 26.5
Ferritin, ng/mL 0.4 0.01
Mean 5353± 2464 4630± 2777 3317± 357 5501± 353 5673± 1063
95% CI 3459 - 7248 4016 - 5245 2590 - 4045 4787 - 6215 3376 - 7971
AST, IU/L 0.2 0.6
Mean 63.3± 4.1 50.5± 3.1 55.5± 7.3 49.1± 3.6 50.5± 8.1
95% CI 31.2 - 95.4 43.4 - 57.5 40.6 - 70.4 41.7- 56.5 32.9 - 68.2
ALT, IU/L 0.9 0.6
Mean 60.5± 3.9 58.6± 6 64.9± 12.3 58± 8.4 46.7± 7.9
95% CI 29.9 - 91.2 45.2 - 72.1 39.7 - 90 40.9 - 75.1 29.6 - 63.8
Abbreviations: ALT, alanine transaminase; Anti-HCV1, anti-hepatitis C virus; AST, aspartate transaminase.
compared to that of the patients < 10 years old; however,
the differences of mean values of hepatic enzymes were
not of statistically significant in different age groups (Table
3). In addition, significant difference of mean ferritin value
was noticed regarding spleen status (Table 4). In contrast,
mean levels of hepatic enzymes were not statistically dif-
ferent regarding either spleen or liver conditions. Tables
3 and 4 represent stratified description of mean age, fer-
ritin and hepatic enzymes regarding anti-HCV status, and
spleen or liver conditions.
5. Discussion
Successive long-term transfusions expose patients
with β-TM to the risk of infections with a wide range of
pathogens including hepatitis. In recent decade, effective
vaccination and screening procedures resulted in remark-
able reduction in hepatitis B virus (HBV) transmission
through blood products. However, hepatitis C virus (HCV)
is still encountered in a relatively high ratio of blood
recipients (7). HCV is responsible for 90% of transfusion
related non-A and non-B hepatitis infections worldwide
(8). It is estimated that 3% of the world population are
exposed to HCV virus (9). Furthermore, HCV infection
may cause a complicated situation in patients with β-TM
through aggravation of iron-induced organ damage (10).
It is mentioned that some current anti-viral treatments
against HCV infection can induce RBC hemolysis, which
accentuate iron overload (11). On the other hand, HCV
infection and iron toxicity may cooperate to accelerate de-
velopment of chronic liver abnormalities such as fibrosis
and cirrhosis in patients with β-TM (8, 10, 12).
Anti-HCV was detected in 10% of the patients with β-
TM in the current study. It was lower than the ratio de-
scribed in some previous studies in North of the country
(13, 14), but similar to the rate obtained in the study per-
formed on Iranian patients by Tamaddoni et al. (15). Higher
incidence of HCV infection in the northern regions may be
partly due to high ratio of individuals with HCV infection
harboring in general population of the areas (16). Further-
more, positivity for anti-HCV was as high as 33% in stud-
ies conducted on Iranian patients with thalassemia major
before 2000; however, this ratio was reported to have de-
creased to 15% - 19% in recent years (6). In other studies on
Iranian patients, anti-HCV was described in range of 6% -
8% in patients with thalassemia (17, 18). Moreover, in the
studies carried out in Thailand (8) and Jordan (19), anti-
HCV frequencies were 20% and 40% respectively in patients
with thalassemia. Collectively, these results indicate the ef-
ficiency of blood donor screening programs in decreasing
transmission of HCV infection over the past decade in Iran.
However, more sophisticated strategies should be imple-
mented to minimize the risk of transmission of infections
by blood transfusion.
In the current study, anti-HCV positivity was signifi-
cantly associated both with age and spleen condition of
the patients (Table 1). Patients with positive results for
anti-HCV were older than the ones with negative results
by a mean difference of six years (Table 2, P = 0.02). A pre-
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Table 4. Mean Values of Age, Ferritin and Hepatic Enzymes Respective to Liver or Spleen Clinical Status
Characteristics Liver P Spleen P
Normal (N = 78) Hepatomegaly (N = 12) Normal (N = 33) Splenectomy (N = 30) Splenomegaly (N = 27)
Age, y 0.04 0.01
Mean 14.2± 7.6 18.8± 4.5 10.5± 8.4 19.5± 3.5 14.8± 6.2
95% CI 24.4 - 15.9 15.9 - 21.7 7.5 - 13.5 18.2 - 20.8 12.3 - 17.2
Ferritin, ng/mL 0.2 0.01
Mean 4567± 2780 5587± 2403 3579± 2124 5270± 2266 5445± 3453
95% CI 3940 - 5194 4060 - 7115 2826 - 4333 4424 - 6117 4079 - 6811
AST, IU/L 0.9 0.8
Mean 51.3± 3.4 54.5± 2.4 51.7± 3.1 54.2± 2.8 49.1± 3.9
95% CI 43.7 - 59 38.7 - 70.2 40.4 - 62.9 43.5 - 64.9 33.6 - 64.6
ALT, IU/L 0.7 0.6
Mean 59.1± 6.1 56.9± 4.1 55± 4.2 55.3± 3.5 67.5± 9
95% CI 45.3 - 73 30.4 - 83.4 40.1 - 69.9 41.9 - 68.6 31.6-103.3
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase.
vious study in Iran also demonstrated that anti-HCV pos-
itive patients were significantly older compared to anti-
HCV negative ones (20). Similarly, patients who had anti-
HCV-positive results were significantly older than anti-
HCV-negative ones in a study carried out in Oman (21). In
addition, previous studies suggested the HCV infection as
a strongly age dependent complication in patients withβ-
TM (22). Therefore, it is beneficial to consider performing
regular occasional screenings for HCV infection especially
in older patients with β-TM.
In addition, spleen condition is suggested as a risk fac-
tor associated with HCV infection in patients with β-TM.
Results of the current study also supported this hypothe-
sis since a significant relationship was observed between
spleen status and anti-HCV positivity. On the contrary, Ah-
mad Akbari et al. found no association between spleen
state and HCV positivity in a study on the Iranian patients
with thalassemia major and intermediate (23). Neverthe-
less, it seems that splenectomy may potentially boost the
risk of HCV infection in higher ages; therefore, it is recom-
mended to postpone this procedure as long as possible in
patients with β-TM.
Additionally, it was also observed that serum ferritin
level was higher in anti-HCV positive patients with β-TM
(Table 2); however, the difference was not statistically sig-
nificant (P > 0.05). In parallel, serum ferritin level was sig-
nificantly higher in anti-HCV positive patients with β-TM
in a systemic multivariate analysis in Iran (7). Neverthe-
less, ferritin value is also highly dependent on different fac-
tors including efficacy of chelation therapy which should
be considered when studying the effects of HCV infection
on ferritin level.
It is established that HCV infection also contributes in
liver dysfunction and deranged levels of hepatic enzymes.
Although mean levels of hepatic enzymes were higher in
anti-HCV positive patients in the current study (Table 2),
the difference was statistically insignificant. In another
study in Iran, also no association was detected between the
level of hepatic enzymes and HCV infection (14). In compar-
ison, anti-HCV positive patients had significantly higher
AST and ALT levels in a study on Thai patients (8). Con-
sidering intercalated relationships between hepatic func-
tion and both HCV infection and iron-burden of liver; more
studies are necessitated in order to establish the role of
these factors in pathogenesis of liver dysfunction in β-TM.
Frequency of HBs antigen positivity was 3.3%% in the
current study. This was higher than the results recorded
by Wanachiwanawin et al. (8) and Karimi et al. (24). On the
other hand, the current study results showed lower preva-
lence in comparison to a study carried out on Indian pa-
tients (25). Regardless of the above mentioned facts, high
prevalence of HBs antigen positivity in the current study
patients highlights requirements for more intense screen-
ing procedures to minimize the ratio as much as possible.
Reactivity for anti-HBs occurred in a high proportion (91%)
of the patients evaluated in the present study. Accordingly,
negative HBs antigen results and also lack of previous vac-
cination in majority of anti-HBs positive patients raise the
challenges regarding the source of these antibodies. It is
suggested that these antibodies may be passively transmit-
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ted from immunized blood donors. This phenomenon is
plausible because of the vaccination programs performed
on normal Iranian populations in past years (26).
5.1. Conclusions
Considering the high rate of HCV infection in the
present study, it is recommended to screen the patients
with appropriate tests on a routine basis. Regarding the
lower rate of HBs antigen positivity, it seems that reactiv-
ity of anti-HBs, especially in younger patients, originates
from passively transmitted antibodies rather than true in-
fection; however, cautious vaccination is appropriate in
such patients.
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